Douglas Carr Email & Phone Number

Doylestown, Pa, Us

Philadelphia, Pennsylvania, Us

• Co-led the company’s initial public offering, including accounting and regulatory preparations, marketing strategy, syndication and investor roadshow presentation.• Supported and managed equity financing transactions totaling approximately $500 million and debt transactions totaling approximately $30 million• Managed efficient Sarbanes-Oxley implementation and continued compliance that was scalable to future growth potential and stage of company development.• Designed and implemented accounting, budgetary and financial forecasting process in support of corporate objectives and strategic plan.• Oversaw implementation and participate in the direction of strategy for information technology infrastructure and security, including implementation of the Company’s ERP system.• Secured and oversaw build-out and supervise operations for facility in support of growth objectives.• Direct company risk management practices and insurance program.

Novira was a privately held biopharmaceutical company focused on discovery and development of first-in-class antiviral drug candidates for the treatment of chronic HBV infection (CHB), a global disease with a high level of unmet medical need. The Company employed innovative chemistry and biology to discover small molecule inhibitors of the HBV core or capsid protein as well as other drug candidates with novel mode of action to be used either as mono-therapy or in combination with existing standards of care. In December 2015, Johnson & Johnson acquired Novira for an undisclosed amount. Overall responsibility for Novira’s financial functions, including Treasury, Financial Planning and Analysis, Accounting, Tax, and Risk Management.Selected key financing and business development accomplishments:Played a key role for overall financing strategy, deal negotiation, and transaction execution:• December 2014: completed $9 million convertible bridge financing with inside investors.• December 2015: Participated in negotiation and execution of Johnson & Johnson acquisition to include: valuation (including coordination with investment bankers); lead in due-diligence processes; lead for transition/integration activities.

Princeton, Nj, Us

Omthera was an emerging specialty pharmaceuticals company focused on the development and commercialization of new therapies for abnormalities in blood lipids, referred to as dyslipidemia, and dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease. In July 2013, AstraZeneca acquired Omthera for a total acquisition consideration of $443 million.Primarily responsible for all finance and administrative functions. Selected key financing and business development accomplishments:Played a key role for overall financing strategy, deal negotiation, and transaction execution:• October 2009: completed $6 million Series A financing.• February 2011: completed $50 million Series B financing.• February 2013: completed $17.6 million convertible bridge financing with inside investors and T. Rowe Price public fund.• March 2013: completed $12.5 million senior secured term loan facility.• April 2013: completed $64 million IPO transaction.- Responsible for drafting S-1 prospectus and creation of all corporate governance and internal accounting policies for public company qualification.- Developed the forecast model and Company valuation (including coordination with sell-side equity research to support IPO).• July 2013: Participated in negotiation and execution of AstraZeneca acquisition to include: valuation (including coordination with investment bankers); participation in due-diligence processes; responsible for all public filings; lead/liaison for transition/integration activities.

Rahway, New Jersey, Us

Rahway, New Jersey, Us

Primarily responsible for ensuring adequate financial controls and providing effective management reporting for USHH financial results and forecasts with oversight for over $14 billion in sales and $2 billion in expenses.

Rahway, New Jersey, Us

Participated on the franchise teams for COZAAR/HYZAAR and ZOCOR as finance business partner to analyze and manage the franchise P&L performance versus profit plan and monthly estimates

Responsible for Managed Care and Competitive Intelligence activities for Hypertension Franchise

Rahway, New Jersey, Us

Responsible for day-to-day operations management of the ZOCOR Franchise (over $6 billion in sales), including forecasting, reporting, budget management and product/sample supply

Provided financial evaluation and analysis of business development initiatives, capital investment decisions and other business projects. Managed the development of the Asia Pacific long range operating plan, annual Profit Plan, monthly forecasts and actuals. Monitored and analyzed monthly performance.

Rahway, New Jersey, Us

Coordinated the preparation and review of the Monthly Operating Book/Board Report; Coordinated and prepared the Quarterly Earnings Release and related management package, as well as the CFO’s Quarterly Financial Results Board presentation.

Responsibilities included monitoring and responding to new accounting and reporting regulations issued by the SEC, FASB and AICPA; applying accounting rules to transactions, and developing internal policies and procedures.

Gb

Controlled all aspects of multinational and local financial services. Managed multiple engagements concurrently, with responsibilities including accounting, auditing and SEC compliance; financial statement preparation; engagement planning; supervising; fee negotiation, billing and collection; new service proposals and client development